|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Smolarz B, Nowak AZ and Romanowicz H:
Breast cancer-epidemiology, classification, pathogenesis and
treatment (Review of Literature). Cancers (Basel). 14:25692022.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cao W, Chen HD, Yu YW, Li N and Chen WQ:
Changing profiles of cancer burden worldwide and in China: A
secondary analysis of the global cancer statistics 2020. Chin Med J
(Engl). 134:783–791. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fan X, Zhang B, He Y, Zhou X, Zhang Y, Ma
L, Li X and Wu J: Burden of disease due to cancer-China, 2000–2019.
China CDC Wkly. 4:306–311. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mahanani MR, Valkov M, Agaeva A, Kaucher
S, Pikalova LV, Grishchenko MY, Zhuikova LD, Jaehn P and Winkler V:
Comparison of female breast cancer between Russia and Germany: A
population-based study on time trends and stage at diagnosis.
Cancer Epidemiol. 80:1022142022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Miller KD, Nogueira L, Devasia T, Mariotto
AB, Yabroff KR, Jemal A, Kramer J and Siegel RL: Cancer treatment
and survivorship statistics, 2022. CA Cancer J Clin. 72:409–436.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jani C, Salcicciol I, Rupal A, Al Omari O,
Goodall R, Salciccioli JD, Marshall DC, Hanbury G, Singh H,
Weissmann L and Shalhoub J: Trends in breast cancer mortality
between 2001 and 2017: An observational study in the European Union
and the United Kingdom. JCO Glob Oncol. 7:1682–1693. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu W, Hurley J, Roberts D, Chakrabortty
SK, Enderle D, Noerholm M, Breakefield XO and Skog JK:
Exosome-based liquid biopsies in cancer: Opportunities and
challenges. Ann Oncol. 32:466–477. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu M, Mo F, Song X, He Y, Yuan Y, Yan J,
Yang Y, Huang J and Zhang S: Exosomal hsa-miR-21-5p is a biomarker
for breast cancer diagnosis. PeerJ. 9:e121472021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang X, Qian T, Bao S, Zhao H, Chen H,
Xing Z, Li Y, Zhang M, Meng X, Wang C, et al: Circulating exosomal
miR-363-5p inhibits lymph node metastasis by downregulating PDGFB
and serves as a potential noninvasive biomarker for breast cancer.
Mol Oncol. 15:2466–2479. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Peng X, Liu Y, Hao R, Zhao R, Zhang
L, Zhao F, Liu Q, Liu Y and Qi Y: The diagnostic value of serum
exosomal Has_circ_0000615 for breast cancer patients. Int J Gen
Med. 14:4545–4554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Di Modugno F, DeMonte L, Balsamo M, Bronzi
G, Nicotra MR, Alessio M, Jager E, Condeelis JS, Santoni A, Natali
PG and Nisticò P: Molecular cloning of hMena (ENAH) and its splice
variant hMena+11a: Epidermal growth factor increases their
expression and stimulates hMena+11a phosphorylation in breast
cancer cell lines. Cancer Res. 67:2657–2665. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ahuja N, Ashok C, Natua S, Pant D, Cherian
A, Pandkar MR, Yadav P, Vishnu NSS, Mishra J, Samaiya A and Shukla
S: Hypoxia-induced TGF-β-RBFOX2-ESRP1 axis regulates human MENA
alternative splicing and promotes EMT in breast cancer. NAR Cancer.
2:zcaa0212020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng Y, Cao Y, Liu L, Zhao J, Zhang T,
Xiao L, Jia M, Tian Q, Yu H, Chen S and Cai Y: SEPT9_i1 regulates
human breast cancer cell motility through cytoskeletal and RhoA/FAK
signaling pathway regulation. Cell Death Dis. 10:7202019.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Devlin L, Okletey J, Perkins G, Bowen JR,
Nakos K, Montagna C and Spiliotis ET: Proteomic profiling of the
oncogenic septin 9 reveals isoform-specific interactions in breast
cancer cells. Proteomics. 21:e21001552021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lu C, Zhao Y, Wang J, Shi W, Dong F, Xin
Y, Zhao X and Liu C: Breast cancer cell-derived extracellular
vesicles transfer miR-182-5p and promote breast carcinogenesis via
the CMTM7/EGFR/AKT axis. Mol Med. 27:782021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kavarthapu R, Anbazhagan R and Dufau ML:
Crosstalk between PRLR and EGFR/HER2 signaling pathways in breast
cancer. Cancers (Basel). 13:46852021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hong OY, Jang HY, Lee YR, Jung SH, Youn HJ
and Kim JS: Inhibition of cell invasion and migration by targeting
matrix metalloproteinase-9 expression via sirtuin 6 silencing in
human breast cancer cells. Sci Rep. 12:121252022. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cancemi P, Buttacavoli M, Roz E and Feo S:
Expression of alpha-enolase (ENO1), Myc promoter-binding protein-1
(MBP-1) and matrix metalloproteinases (MMP-2 and MMP-9) reflect the
nature and aggressiveness of breast tumors. Int J Mol Sci.
20:39522019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mishra A, Suman KH, Nair N, Majeed J and
Tripathi V: An updated review on the role of the CXCL8-CXCR1/2 axis
in the progression and metastasis of breast cancer. Mol Biol Rep.
48:6551–6561. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ruffini PA: The CXCL8-CXCR1/2 axis as a
therapeutic target in breast cancer stem-like cells. Front Oncol.
9:402019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang RX, Ji P, Gong Y, Shao ZM and Chen S:
Value of CXCL8-CXCR1/2 axis in neoadjuvant chemotherapy for
triple-negative breast cancer patients: A retrospective pilot
study. Breast Cancer Res Treat. 181:561–570. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Breast Cancer Committee of Chinese
Anti-Cancer Association, . Chinese Anti-Cancer Association Breast
Cancer Diagnosis and Treatment Guidelines and Standards (2021).
China Oncology. 31:954–1040. 2021.
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han C, Bellone S, Siegel ER, Altwerger G,
Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A,
Riccio F, et al: A novel multiple biomarker panel for the early
detection of high-grade serous ovarian carcinoma. Gynecol Oncol.
149:585–591. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo C, Wang L, Zhang Y, Lu M, Lu B, Cai J,
Chen H and Dai M: Advances in breast cancer screening modalities
and status of global screening programs. Chronic Dis Transl Med.
8:112–123. 2022.PubMed/NCBI
|
|
27
|
Ren W, Chen M, Qiao Y and Zhao F: Global
guidelines for breast cancer screening: A systematic review.
Breast. 64:85–99. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding R, Xiao Y, Mo M, Zheng Y, Jiang YZ
and Shao ZM: Breast cancer screening and early diagnosis in Chinese
women. Cancer Biol Med. 19:450–467. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mann RM, Hooley R, Barr RG and Moy L:
Novel approaches to screening for breast cancer. Radiology.
297:266–285. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Shu L, Niu N, Zhao C, Lu S, Li Y,
Wang H, Liu Y, Zou T, Zou J, et al: Novel lncRNAs with diagnostic
or prognostic value screened out from breast cancer via
bioinformatics analyses. PeerJ. 10:e136412022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jia L, Li G, Ma N, Zhang A, Zhou Y, Ren L
and Dong D: Soluble POSTN is a novel biomarker complementing CA153
and CEA for breast cancer diagnosis and metastasis prediction. BMC
Cancer. 22:7602022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Veyssiere H, Bidet Y, Penault-Llorca F,
Radosevic-Robin N and Durando X: Circulating proteins as predictive
and prognostic biomarkers in breast cancer. Clin Proteomics.
19:252022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Na-Er A, Xu YY, Liu YH and Gan YJ:
Upregulation of serum exosomal SUMO1P3 predicts unfavorable
prognosis in triple negative breast cancer. Eur Rev Med Pharmacol
Sci. 25:154–160. 2021.PubMed/NCBI
|
|
34
|
Lakshmi S, Hughes TA and Priya S: Exosomes
and exosomal RNAs in breast cancer: A status update. Eur J Cancer.
144:252–268. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zokaei E, Darbeheshti F and Rezaei N:
Prospect of exosomal circular RNAs in breast cancer: Presents and
future. Mol Biol Rep. 49:6997–7011. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li QL, Su YL, Zeng M and Shen WX: Enabled
homolog shown to be a potential biomarker and prognostic indicator
for breast cancer by bioinformatics analysis. Clin Invest Med.
41:E186–E195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Matsui S, Kagara N, Mishima C, Naoi Y,
Shimoda M, Shimomura A, Shimazu K, Kim SJ and Noguchi S:
Methylation of the SEPT9_v2 promoter as a novel marker for the
detection of circulating tumor DNA in breast cancer patients. Oncol
Rep. 36:2225–2235. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Khambri D, Suyuthie HD, Hilbertina N,
Yetti H and Purwanto DJ: Matrix metalloproteinase-9 as prognostic
factor for the treatment of HER-2 enriched breast cancer. Asian Pac
J Cancer Prev. 23:1013–1021. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yotsumoto F, Tokunaga E, Oki E, Maehara Y,
Yamada H, Nakajima K, Nam SO, Miyata K, Koyanagi M, Doi K, et al:
Molecular hierarchy of heparin-binding EGF-like growth
factor-regulated angiogenesis in triple-negative breast cancer. Mol
Cancer Res. 11:506–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Fang QI, Wang X, Luo G, Yu M, Zhang X and
Xu N: Increased CXCL8 expression is negatively correlated with the
overall survival of patients with ER-Negative breast cancer.
Anticancer Res. 37:4845–4852. 2017.PubMed/NCBI
|
|
41
|
Melchionna R, Iapicca P, Di Modugno F,
Trono P, Sperduti I, Fassan M, Cataldo I, Rusev BC, Lawlor RT,
Diodoro MG, et al: The pattern of hMENA isoforms is regulated by
TGF-β1 in pancreatic cancer and may predict patient outcome.
Oncoimmunology. 5:e12215562016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wasserkort R, Kalmar A, Valcz G, Spisak S,
Krispin M, Toth K, Tulassay Z, Sledziewski AZ and Molnar B:
Aberrant septin 9 DNA methylation in colorectal cancer is
restricted to a single CpG island. BMC Cancer. 13:3982013.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bai C, Ma X, Wang X and Chen X:
Correlation between pathological features and protein expressions
of TfR1, VEGF and MMP-9 in patients with osteosarcoma. Am J Transl
Res. 14:4562–4572. 2022.PubMed/NCBI
|
|
44
|
Kong L, Qi R, Zhou G and Ding S:
Correlation analysis of survivin, ING4, CXCL8 and VEGF expression
in prostate cancer tissue. Am J Transl Res. 13:13784–13790.
2021.PubMed/NCBI
|
|
45
|
Hacisalihoglu UP and Dogan MA: Expression
of estrogen and progesterone receptors, HER2 protein and Ki-67
proliferation index in breast carcinoma in both tumor tissue and
tissue microarray. Biotech Histochem. 97:298–305. 2022. View Article : Google Scholar : PubMed/NCBI
|
